<VariationArchive VariationID="1458083" VariationName="NC_000017.10:g.(?_17107268)_(17125891_?)del" VariationType="Deletion" Accession="VCV001458083" Version="6" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-06-10" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1471649" VariationID="1458083">
      <GeneList>
        <Gene Symbol="FLCN" FullName="folliculin" GeneID="201163" HGNC_ID="HGNC:27310" Source="submitted" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>17p11.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="17212212" stop="17237330" display_start="17212212" display_stop="17237330" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="17115525" stop="17140501" display_start="17115525" display_stop="17140501" Strand="-" />
          </Location>
          <OMIM>607273</OMIM>
          <Haploinsufficiency last_evaluated="2023-01-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FLCN">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2023-01-11" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=FLCN">No evidence available</Triplosensitivity>
        </Gene>
        <Gene Symbol="PLD6" FullName="phospholipase D family member 6" GeneID="201164" HGNC_ID="HGNC:30447" Source="calculated" RelationshipType="genes overlapped by variant">
          <Location>
            <CytogeneticLocation>17p11.2</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="17" Accession="NC_000017.11" start="17200995" stop="17206333" display_start="17200995" display_stop="17206333" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" start="17104308" stop="17109645" display_start="17104308" display_stop="17109645" Strand="-" />
          </Location>
          <OMIM>614960</OMIM>
        </Gene>
      </GeneList>
      <Name>NC_000017.10:g.(?_17107268)_(17125891_?)del</Name>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>17p11.2</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" forDisplay="true" AssemblyStatus="previous" Chr="17" Accession="NC_000017.10" innerStart="17107268" innerStop="17125891" display_start="17107268" display_stop="17125891" variantLength="18624" />
      </Location>
      <HGVSlist>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000017.10" sequenceAccession="NC_000017" sequenceVersion="10" change="g.(?_17107268)_(17125891_?)del" Assembly="GRCh37">
            <Expression>NC_000017.10:g.(?_17107268)_(17125891_?)del</Expression>
          </NucleotideExpression>
        </HGVS>
      </HGVSlist>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NC_000017.10:g.(?_17107268)_(17125891_?)del AND Birt-Hogg-Dube syndrome" Accession="RCV001972794" Version="5">
        <ClassifiedConditionList TraitSetID="860">
          <ClassifiedCondition DB="MedGen" ID="C0346010">Birt-Hogg-Dube syndrome</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-09-05" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-09-05" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-06-09">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">15852235</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="860" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="1028" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Birt-Hogg-Dube syndrome</ElementValue>
                <XRef ID="MONDO:0800444" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">BHD syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Birt Hogg Dubé syndrome</ElementValue>
                <XRef ID="1263460007" DB="SNOMED CT" />
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">BHD</ElementValue>
                <XRef Type="MIM" ID="135150" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="2322" />
                <XRef ID="2322" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">The clinical characteristics of Birt-Hogg-Dubé syndrome (BHDS) include cutaneous manifestations (fibrofolliculomas, acrochordons, angiofibromas, oral papules, cutaneous collagenomas, and epidermal cysts), pulmonary cysts/history of pneumothorax, and various types of renal tumors. Disease severity can vary significantly even within the same family. Skin lesions typically appear between the second and fourth decades of life and typically increase in size and number with age. Lung cysts are often bilateral and multifocal; most individuals are asymptomatic but at high risk for spontaneous pneumothorax. Individuals with BHDS are at a sevenfold increased risk for renal tumors that can be bilateral and multifocal; median age of renal tumor diagnosis is 48 years. The most common renal tumors are a hybrid of oncocytoma and chromophobe histologic cell types (oncocytic hybrid tumor) and chromophobe histologic cell types. Some families have renal tumor(s) and/or spontaneous pneumothorax without cutaneous manifestations.</Attribute>
                <XRef ID="NBK1522" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301695</ID>
                <ID Source="BookShelf">NBK1522</ID>
              </Citation>
              <Citation Type="general" Abbrev="ACMG/NSGC, 2015">
                <ID Source="PubMed">25394175</ID>
              </Citation>
              <Citation Type="general" Abbrev="KCRNC, 2013">
                <ID Source="PubMed">24319509</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Renal cell carcinoma genetics">
                <ID Source="PubMed">26389510</ID>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Birt-Hogg-Dubé syndrome">
                <URL>https://www.cancer.gov/types/kidney/hp/renal-cell-carcinoma-genetics/bhd-syndrome</URL>
                <CitationText>PDQ® Cancer Genetics Editorial Board. PDQ Birt-Hogg-Dubé Syndrome. Bethesda, MD: National Cancer Institute. Updated &lt;03/08/2021&gt;. Accessed &lt;05/05/2021&gt;.</CitationText>
              </Citation>
              <Citation Type="Suggested Reading" Abbrev="NCI PDQ, Cancer Genetics Counseling">
                <ID Source="PubMed">26389258</ID>
              </Citation>
              <XRef ID="122" DB="Orphanet" />
              <XRef ID="C0346010" DB="MedGen" />
              <XRef ID="MONDO:0800444" DB="MONDO" />
              <XRef Type="Phenotypic series" ID="PS135150" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4265348" SubmissionDate="2024-06-04" DateLastUpdated="2024-06-09" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="NM_144997.5_17_Partial deletion (exons 7-14)_17107267_17125891|MedGen:C0346010" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002239057" DateUpdated="2024-06-09" DateCreated="2022-03-28" Type="SCV" Version="4" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-09-05">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Citation>
            <ID Source="PubMed">15852235</ID>
          </Citation>
          <Comment>This variant results in the deletion of exons 8-14 and part of exon 7 (c.703_*9701delinsCTAC) of the FLCN gene. While this deletion is not anticipated to lead to nonsense mediated decay, it is expected to alter mRNA translation or result in a truncated protein product. For these reasons, this variant has been classified as Pathogenic. This variant disrupts a region of the FLCN protein in which other variant(s) (p.Arg527*) have been determined to be pathogenic (PMID: 15852235; Invitae). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. This variant has not been reported in the literature in individuals affected with FLCN-related conditions.</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="FLCN" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000017.10:g.(?_17107268)_(17125891_?)del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0346010" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12699154</SubmissionName>
          <SubmissionName>SUB14505679</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4265348" TraitType="Disease" MappingType="XRef" MappingValue="C0346010" MappingRef="MedGen">
        <MedGen CUI="C0346010" Name="Birt-Hogg-Dube syndrome" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

